$546.75−2.70 (−0.49%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Chemed (CHE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~4.3%/yr (FY21→FY25), net margin 10.5%, and free cash flow (~$325.5M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (142%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲4.1%
2,530.0
FY21→FY25CAGR +4.3%/yr
Net income ($M)▼12.2%
265.2
FY21→FY25CAGR −0.3%/yr
Free cash flow ($M)▼11.5%
325.5
FY21→FY25CAGR +6.8%/yr
Diluted EPS▼7.8%
18.34
buyback-liftedCAGR +2.1%/yr
What the receipts whisper · what a headline number hides
Share count
−9.3%
15.9mn → 14.5mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$62.8M
+26.8% YoY in FY25 · 2.5% of revenue.
Returns vs FCF
142%
$463.2M returned vs $325.5M of FCF in FY25. The gap comes off the balance sheet (see net cash).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
10¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 36.0% → 32.5%. Net margin 10.5% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 2,661.0 | 2,530.0 | 2,431.3 | 2,264.4 | 2,135.0 | 2,139.3 | ▲4.1% | +4.3% |
Cost of revenue | 1,768.5 | 1,706.8 | 1,576.9 | 1,465.6 | 1,369.9 | 1,369.5 | ▲8.2% | +5.7% |
Gross profit | 892.5 | 823.2 | 854.3 | 798.8 | 765.1 | 769.8 | ▼3.6% | +1.7% |
Selling, general & admin | 446.5 | 417.2 | 424.4 | 395.1 | 358.7 | 366.7 | ▼1.7% | +3.3% |
Total operating expenses | 521.7 | 484.9 | 487.9 | 458.2 | 421.6 | 426.8 | ▼0.6% | +3.2% |
Operating incomefeeds ROC rank | 370.9 | 338.2 | 366.5 | 340.6 | 343.5 | 343.0 | ▼7.7% | −0.4% |
Other income, net | 11.5 | 17.5 | 33.0 | 9.8 | −13.8 | 7.3 | — | — |
Pretax income | 382.3 | 355.8 | 399.5 | 350.4 | 329.7 | 350.3 | ▼10.9% | +0.4% |
Income tax | 99.9 | 90.5 | 97.5 | 77.9 | 80.1 | 81.8 | ▼7.1% | +2.6% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 282.4 | 265.2 | 302.0 | 272.5 | 249.6 | 268.6 | ▼12.2% | −0.3% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 20.87 | 18.34 | 19.89 | 17.93 | 16.53 | 16.85 | ▼7.8% | +2.1% |
Diluted shares (mn) | 13.13 | 14.46 | 15.19 | 15.20 | 15.10 | 15.94 | ▼4.8% | −2.4% |
| Margins | ||||||||
Gross margin17th pct in Healthcare | 33.5% | 32.5% | 35.1% | 35.3% | 35.8% | 36.0% | ▼2.6pp | −3.4pp |
Operating margin | 13.9% | 13.4% | 15.1% | 15.0% | 16.1% | 16.0% | ▼1.7pp | −2.7pp |
Net margin70th pct in Healthcare | 10.6% | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | ▼1.9pp | −2.1pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Chemed's revenue last fiscal year?
Chemed reported revenue of $2,530.0M in fiscal 2025, up 4.1% from fiscal 2024.
What was Chemed's net income?
Chemed reported net income of $265.2M in fiscal 2025, a net margin of 10.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

